Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage
Cytochrome P450s are key players in drug metabolism, and overexpression in tumors is associated with significant resistance to many medicinal agents. Consequently, inhibition of P450s could serve as a strategy to restore drug efficacy. However, the widespread expression of P450s throughout the human body and the critical roles they play in various biosynthetic pathways motivates the development of P450 inhibitors capable of controlled local administration. Ruthenium complexes containing P450 inhibitors as ligands were synthesized in order to develop pro-drugs that can be triggered to release the inhibitors in a spatially and temporally controlled fashion. Upon light activation the compounds release ligands that directly bind and inhibit P450 enzymes, while the ruthenium center is able to directly damage DNA.
Zamora, Ana,Denning, Catherine A.,Heidary, David K.,Wachter, Erin,Nease, Leona A.,Ruiz, José,Glazer, Edith C.
p. 2165 - 2173
(2017/02/26)
ONE-STEP PROCESS FOR THE SYNTHESIS OF ALKYLATED METYRAPONE ANALOGS
Process for preparing metyrapone type compounds are generally described herein. In particular, one step process for preparing metyrapone type compounds are described herein. Such processes generally include an alpha-carbon arylation coupling reaction between 3-isobutyrylpyridine and 3-halopyridine compounds in the presence of a palladium catalyst and a phosphine ligand to form the metyrapone-type compounds.
-
Paragraph 0026
(2016/07/27)
Mechanism of the pinacol-pinacolone rearrangement of 2,3-di-(3-pyridyl)-2,3-butanediol in sulfuric acid
The reaction of 2,3-di-(3-pyridyl)-2,3-butanediol (1) in H2SO4 was studied. It was found that the meso and racemic forms give mono- and bis-SO3 addition products, which rearrange to a ketone (Metopirone) and two other majo